C-CAR031 is based on a novel GPC3-targeting CAR-T (AZD5851) designed by AstraZeneca using their transforming growth factor-beta receptor II
Impressive safety and efficacy for solid cancer patients followed by global clinical study plan
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
Astria will assume full cost and responsibility for the global development and commercialization of the licensed therapeutic program for all indications
BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials
Zurletrectinib was developed to treat advanced or metastatic solid tumors harboring NTRK fusion genes
Cullgen will have the option during the initial stages of clinical development to participate equally in the costs, profits and losses
UTD2 is the world's first oral epothilone microtubule inhibitor
Nous-209 has been developed using the Nouscom's viral vector platform
From cancer research to diagnostic solutions
Subscribe To Our Newsletter & Stay Updated
